Ipamorelin

A selective growth hormone secretagogue researched for stimulating the body’s own GH release with minimal effect on cortisol and prolactin.

Typical bottle: 10 mg

Research note: Ipamorelin’s relative receptor selectivity is well documented mechanistically, but as with most GH secretagogues, most protocol-level dosing guidance comes from research communities rather than large controlled human trials.

What It Is

Ipamorelin is a growth hormone secretagogue researched for its ability to stimulate the body’s natural release of growth hormone. Unlike some older GH-releasing compounds, it is known for relative selectivity for the growth hormone secretagogue receptor (GHS-R), making it interesting for research into GH release with less stimulation of other hormones such as cortisol and prolactin.

Ipamorelin does not directly provide growth hormone — it works by encouraging the pituitary gland to release more of the body’s own supply, which is researched for potential effects on recovery, body composition, tissue repair, sleep, and healthy aging.

Who May Benefit

Recovery from training
Muscle recovery and development
Body composition research
Fat metabolism
Tissue repair
Sleep and overnight recovery
Growth hormone signaling research
Healthy aging

What to Expect

Ipamorelin is generally approached as a consistent, longer-term research protocol rather than something expected to produce an immediate effect.

Research interest centers on growth hormone signaling, recovery, sleep quality, body composition, and tissue-repair processes. Response varies with age, baseline GH activity, sleep quality, nutrition, and training.

What to Pair It With

CJC-1295 + Ipamorelin

Combining with a GHRH analog provides a complementary mechanism for a broader GH-axis protocol.

BPC-157

Tissue repair and inflammatory regulation complement a recovery-focused GH protocol.

TB-500

Cellular migration and tissue repair research pairs with Ipamorelin’s recovery focus.

GHK-Cu

Collagen production and tissue remodeling complement GH-axis skin and connective-tissue research.

Reconstitution

Vial

10 mg

Diluent

1 mL Bac. Water

Final Concentration

10 mg/mL

5 units = 500 mcg10 units = 1 mg

Suggested Research Dosing Strategy

Standard / Lower Range

500 mcg (5 units)

Once daily · subcutaneous administration.

Advanced Range

1 mg (10 units)

Once daily · subcutaneous administration.

Suggested research cycle: 12–16 weeks ON, followed by approximately 4 weeks OFF. A 10 mg vial provides roughly 20 doses at 500 mcg or 10 doses at 1 mg.

Administration Notes

Subcutaneous administration is commonly used. A fasted state may be incorporated depending on the research objective.

Evening or pre-bedtime administration is common when sleep and overnight recovery are the primary research goals, since natural GH release is closely tied to sleep.

If noticeable water retention occurs, the protocol should be reassessed rather than automatically increasing the dose.

Research Considerations

Ipamorelin’s relative selectivity for the GHS-R receptor is a major reason it’s favored in GH-axis research — the goal is to stimulate the body’s own GH signaling while minimizing unnecessary stimulation of other hormonal pathways.

Growth hormone influences tissue repair, protein metabolism, fat metabolism, sleep, and IGF-1 signaling broadly, but more GH/IGF-1 signaling is not automatically better — response and tolerability matter in longer protocols.

Have a specific question about Ipamorelin? Chat with Pulse, Signal IQ’s free AI research assistant — ask about mechanisms, stacking, or how it compares to other compounds.

For research purposes only. Not approved for human use. This information is provided for educational and research purposes and is not medical advice. Signal IQ does not sell peptides.

All Peptides by Goal